CurrentAvMedPolicy N/A

Prior authorization and step-edit criteria for rituximab products

Prior authorization and step-edit criteria for medical (infused) rituximab products for AvMed members, specifying clinical indications, required prescriber specialty, prior therapy, documentation, and authorization durations.

Policy Summary

PayerAvMed

PolicyPrior authorization and step-edit criteria for rituximab products

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionSubmit a completed prior authorization form with prescriber signature and supporting documentation (labs, diagnostics, chart notes) to avoid denial.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 moInitial authorization duration

12 moReauthorization duration

3 moRA methotrexate trial

≤24 moGPA/MPA maintenance max

18+NMOSD minimum age

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Rheumatoid Arthritis - Initial Approval Criteria

Covered when ALL of the following are met:

RA_prescriber: Prescriber is a rheumatologist

RA_diagnosis: Member has a diagnosis of moderate- to-severe rheumatoid arthritis

RA_methotrexate: Trial and failure of at least three (3) months of methotrexate therapy3 months

RA_biologics: Trial and failure of BOTH preferred medical biologics: Renflexis or unbranded infliximab AND Cimzia

GPA/MPA - Initial Therapy Criteria

Covered when ALL of the following are met:

GPA_prescriber: Prescriber is a rheumatologist or nephrologist

GPA_diagnosis: Member has a diagnosis of moderate- to-severe granulomatosis with polyangiitis

GPA_corticosteroids: Member will receive concurrent therapy with corticosteroids

GPA_prior_or_contraindication: Member failed cyclophosphamide therapy OR member has a contraindication to cyclophosphamide therapy

If contraindication, prescriber must document reason.

GPA/MPA - Maintenance Therapy Criteria

Covered when ALL of the following are met:

GPA_maint_prescriber: Prescriber is a rheumatologist or nephrologist

GPA_induction_timing: Induction occurred at least 4 months prior>=4 months

GPA_duration_max: Total duration of treatment does not exceed 24 months<=24 months

GPA_maint_prior: Member failed methotrexate or azathioprine therapy OR member has a contraindication to methotrexate or azathioprine therapy

Neuromyelitis Optica Spectrum Disorder (NMOSD)

Covered when ALL of the following are met:

NMOSD_prescriber: Prescribing physician must be a neurologist

NMOSD_age: Member must be 18 years of age or older>=18 years

NMOSD_serostatus: Member was found to be seropositive for AQP4 IgG antibodies OR member was seronegative/unknown but has at least two core clinical characteristics from one or more clinical attacks

See core clinical characteristics and MRI requirements.

NMOSD_clinical_requirements: At least 1 core clinical characteristic must be optic neuritis, acute myelitis with LETM, or area postrema syndrome; dissemination in space (>=2 different core clinical characteristics); fulfillment of additional MRI requirements as applicable; alternative diagnoses excluded; member failed at least one of azathioprine, methotrexate, mitoxantrone or mycophenolate OR required plasmapheresis/PE or IVIG

Pemphigus Vulgaris - Initial Criteria

Covered when ALL of the following are met:

PV_diagnosis_evidence: Diagnosis confirmed by at least one: clinical features (lesions/blisters), Nikolsky sign, characteristic scarring/distribution, histopathologic biopsy, positive direct immunofluorescence or autoantibodies

Submit documentation.

PV_severity: Member has moderate to severe disease as assessed by an objective tool (e.g., PDAI, PSS, ABSIS)

Submit documentation.

PV_glucocorticoid_combo: Member is on combination glucocorticoid therapy (verified by chart notes and/or pharmacy claims)

Provider must attest other causes of blistering/erosive disease have been ruled out.

Use of samples to initiate therapy does not meet step edit or prior authorization criteria. Providers should not rely on manufacturer samples as evidence of prior therapy when requesting authorization for rituximab products; prior treatments will be verified via pharmacy paid claims or submitted chart documentation.

Requests that do not include the required supporting documentation are at risk for denial. All documentation — including chart notes, relevant laboratory results, and diagnostic reports — must be provided to support each clinical criterion checked on the prior authorization form. Failure to supply these materials may result in the request being denied as not meeting medical necessity evidence requirements.

Provider Actions and Submission Requirements

Prior Authorization

Prior Authorization Required

Medical prior authorization is required for the listed rituximab products. Submit a completed medical PA for any request for these drugs to avoid claim denial.

Affected products: Riabni (rituximab-arrx) Q5123; Rituxan (rituximab) J9312; Ruxience (rituximab-pvvr) Q5119; Truxima (rituximab-abbs) Q5115

Step Therapy

RA Step Therapy Requirement

For rheumatoid arthritis (RA) requests, a 3-month trial and failure of methotrexate is required, and the member must have trialed and failed preferred biologics (Renflexis or unbranded infliximab AND Cimzia) before rituximab will be approved.

Methotrexate trial: ≥ 3 months documented
Preferred biologics required and failed: Renflexis (or unbranded infliximab) AND Cimzia

Documentation Required

Required Submission Items

Use this checklist to ensure the PA request is complete. Incomplete submissions may delay authorization.

Completed PA form with all sections filled
Prescriber signature and NPI
Diagnosis and ICD-10 code
Member identifiers (name, AvMed #, DOB)
Weight and date weight obtained (if applicable)
Dosing schedule and length of therapy
Relevant labs, diagnostics, and chart notes
Documentation of prior therapies and dates (e.g., methotrexate duration, biologic trials)

Denial Risk

Documentation Required to Avoid Denial

Failure to provide the requested supporting documentation (labs, diagnostics, chart notes, prior therapy records) or to meet stated clinical criteria may result in denial of the PA request.

Missing labs or chart notes increases denial risk
Lack of documentation of methotrexate trial or biologic failures for RA will lead to denial
Unsigned or incomplete PA form may delay or cause denial

Background

This policy governs prior authorization and step-edit criteria for medical (infused) rituximab products (Riabni, Rituxan, Ruxience, Truxima) across multiple autoimmune conditions, including rheumatoid arthritis, granulomatosis with polyangiitis/microscopic polyangiitis, neuromyelitis optica spectrum disorder, and pemphigus vulgaris. It defines required prescriber specialties (for example, rheumatologist, nephrologist, or neurologist depending on indication), prior therapy and step-therapy requirements (e.g., for RA: a minimum 3-month trial of methotrexate plus failure of specified preferred biologics), documentation that must accompany requests (diagnosis with ICD code, weight/dosing, chart notes, labs, diagnostics), and authorization durations. Note that use of samples to initiate therapy does not meet the step edit/prior authorization requirement and prior therapies will be verified through pharmacy claims or submitted chart notes.

OpenPayer

Prior authorization and step-edit criteria for rituximab products

Coverage Criteria for Rituximab Products

Coding and Diagnostic Criteria

Provider Actions and Submission Requirements

Definitions and Core Clinical Characteristics

Background

Q5123	Riabni (rituximab-arrx)
J9312	Rituxan (rituximab)
Q5119	Ruxience (rituximab-pvvr)
Q5115	Truxima (rituximab-abbs)